WNK1 plays a crucial role in the body's response to the diuretic hydrochlorothiazide, used for treating hypertension. Variations in the WNK1 gene can influence the drug's effectiveness, as these mutations may increase ion reabsorption in the kidneys' distal tubules, thus potentially diminishing hydrochlorothiazide's efficacy and requiring personalized treatment adjustments.